Institutional members access full text with Ovid®

Share this article on:

Hypofractionation for Prostate Cancer

Ritter, Mark MD, PhD*; Forman, Jeffrey MD; Kupelian, Patrick MD; Lawton, Colleen MD§; Petereit, Daniel MD

doi: 10.1097/PPO.0b013e3181976614
Practice of Oncology: Recent Advances

Hypofractionation for prostate cancer was originally carried out in the pursuit of efficiency and convenience but has now attracted greatly renewed interest based upon a hypothesis that prostate cancers have a higher sensitivity to fraction size, reflected in a low α/β ratio, than do late responding organs at risk such as the rectum or bladder. Tumor control and acceptable toxicity outcomes from several hypofractionation or brachytherapy analyses do in fact support an α/β ratio for prostate cancer that is low, perhaps even lower that that for the normal organs that ordinarily constrain the delivery of radiation therapy. However, many of these studies lack sufficient patient numbers and follow-up, are clouded by dose inhomogeneity issues in the case of brachytherapy, or delivered effective doses that were too low by contemporary standards. Thus, the clinical efficacy of the approach has yet to be fully validated. However, a number of newer prospective trials, some randomized, are underway or have reached accrual but await sufficient follow-up for analysis. These studies, which cover a wide range of doses per fraction, should ultimately be capable of validating the utility of prostate hypofractionation and the models that predict its effects. With hypofractionation's significant potential for therapeutic gain, cost savings, and improved patient convenience, the future management of localized prostate cancer could be profoundly altered in the process.

From the *Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI; †Department of Radiation Oncology, Wayne State University, Detroit, MI; ‡Department of Radiation Oncology, MD Anderson Cancer Center, Orlando, FL; §Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI; and ¶John T. Vucurevich Cancer Care Institute, Rapid City, SD.

Received for publication November 17, 2008; accepted December 3, 2008.

Partially supported in part by NIH grants CA106835 and CA88960.

Reprints: Mark A. Ritter, MD, PhD, Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, 600 Highland Avenue-K4/B100, Madison, WI 53792. E-mail:

© 2009 Lippincott Williams & Wilkins, Inc.